ASOMEX Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

Emcure pharmaceuticals ltd, India

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. ASOMEX-2.5:

    S(-)Amlodipine 2.5mg

    2. ASOMEX-5:

    S(-)Amlodipine 5mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    ・Essential hypertension

    ・Angina pectoris

    Dosage and Administration

    The normal recommended dose is 2.5mg once a day. Based on the clinical response of the patient, the dose may be enhanced up to 5mg once a day.

    Duration of Therapy: S(-) Amlodipine is prescribed as part of therapy for chronic conditions like hypertension and angina. Duration of therapy will be for as long as required and will be decided by treating doctor based on individual response to therapy and tolerability.

  • ហាមប្រើ

    Hypersensitivity to any of the components of the formulation.

  • ផលរំខាន

    On the basis of the clinical data available, following non-serious adverse events with incidence <2% have been reported with the use of S(-) Amlodipine:

    pedal edema, headache, dizziness, asthenia, somnolence, blushing, chest pain, vomiting, abdominal pain, myalgia, rash, frequent urination, palpitation, fever, presyncopy, difficulty in breathing, tachycardia, cough, cheerlessness, facial puffiness, heavy headedness, worsening of hyperlipidemia, impaired glycemic control, and diarrhea.

  • អន្តរប្រតិកម្ម

    Clinical studies have shown that Amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, NSAIDs, antibiotics, and oral hypoglycemic drugs. Hence no such interactions are expected with S(-) Amlodipine.

    The pharmacokinetic studies with fixed dose combinations (FDC) of S(-)Amlodipine with Atorvastatin, Hydrochlorothiazide, Ramipril, Atenolol and S(-) Metoprolol reported no any adverse interaction profile. So the above mentioned drugs can be administered with S(-) Amlodipine as co-prescription or in FDC.

    See the package insert about the details below:

    Atorvastatin

    beta Blockers

    AngiotensinⅡReceptor Antagonist

    Digoxin

    Ethanol (alcohol)

    Warfarin

    Nicotine

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    There is no data available on the use of S(-) Amlodipine in pregnant and lactating women, hence the drug should be administered only when the potential benefits outweighs the risk to the patient.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    No controlled clinical study of S(-) Amlodipine has been performed in patients with hepatic impairment and renal impairment. Clinical studies in patients with normal liver function have shown that there is no elevation in the hepatic enzymes with the use of S(-) Amlodipine. However, caution should be taken while administering S(-) Amlodipine to patients with hepatic and renal impairment.

  • សកម្មភាពឱសថ

    S(-)Amlodipine, the chirally pure form of Amlodipine is a calcium channel antagonist belonging to the dihydropyridine class. The S(-) isomer of Amlodipine is found to possess greater pharmacological effects than R(+) Amlodipine. S(-) Amlodipine is 1000 times more potent than the R(+) isomer in binding to the dihydropyridine receptor. In humans, the dominant effects of Amlodipine are consequent to vasodilation. S(-) Amlodipine lowers peripheral vascular resistance without causing a reflex tachycardia. It is effective as a once daily dosage in the control of hypertension.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp